Baxter International (BAX) reported $2.97 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 8%. EPS of $0.44 for the same period compares to $0.58 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $2.79 billion, representing a surprise of +6.44%. The company delivered an EPS surprise of -17.42%, with the consensus EPS estimate being $0.53.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Baxter performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Pharmaceuticals- International: $478 million versus $437.48 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +11.4% change.
- Geographic Net Sales- United States: $1.55 billion versus $1.51 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +2.8% change.
- Net Sales- Other- International: $35 million versus the three-analyst average estimate of $21.85 million. The reported number represents a year-over-year change of +337.5%.
- Net Sales- Front Line Care- International: $71 million compared to the $71.26 million average estimate based on three analysts. The reported number represents a change of -1.4% year over year.
- Net Sales- Pharmaceuticals: $668 million versus $636.32 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +3.9% change.
- Net Sales- Advanced Surgery: $328 million versus $306.55 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +12.3% change.
- Net Sales- Other: $91 million versus the five-analyst average estimate of $68.32 million. The reported number represents a year-over-year change of +658.3%.
- Net Sales- Front Line Care: $290 million versus the five-analyst average estimate of $285.26 million. The reported number represents a year-over-year change of +3.6%.
- Net Sales- Infusion Therapies and Technologies: $1.06 billion versus the five-analyst average estimate of $959.12 million. The reported number represents a year-over-year change of +3.7%.
- Net Sales- Healthcare Systems and Technologies: $827 million compared to the $806.54 million average estimate based on five analysts. The reported number represents a change of +5.5% year over year.
- Net Sales- Care and Connectivity Solutions: $537 million versus $521.28 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +6.6% change.
- Net Sales- Medical Products and Therapies: $1.39 billion versus $1.27 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +5.6% change.
View all Key Company Metrics for Baxter here>>>
Shares of Baxter have returned +12.3% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Baxter International Inc. (BAX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
